EcoDrugPlus

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSLACG00000008912
Gene Symbol: MAPK10
3 Cross references
147 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSLACG00000015757
Gene Symbol: MAPK11
4 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSLACG00000001584
Gene Symbol: MAPK14
4 Cross references
281 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSLACG00000001255
Gene Symbol: LOC102354262
4 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSLACG00000018583
Gene Symbol: MAPK8
4 Cross references
295 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSLACG00000002222
Gene Symbol: MAPK9
4 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSLACG00000006464
Gene Symbol: MAP2K1
4 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSLACG00000009760
Gene Symbol: MAP2K2
4 Cross references
269 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSLACG00000007337
Gene Symbol: MAP3K1
3 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSLACG00000018827
Gene Symbol: MAP3K10
2 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSLACG00000009593
Gene Symbol: MAP3K11
2 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSLACG00000003330
Gene Symbol: MAP3K12
2 Cross references
254 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).